BackTable Urology
Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay
Dr. Rana McKay
the potential cardiovascular, not to say risk, but mitigated risk with antagonist versus agonist. But I think there's a choice in the matter. Some patients may have a strong preference one way or another, and in which case they do, there's options, which is a good thing. Some patients are very
0
💬
0
Comments
Log in to comment.
There are no comments yet.